Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma [III]. Transcriptomic and metabolic effect of immune checkpoint inhibitors on cellular components in renal cell tumor microenvironment and in Sunitinib resistant renal cell carcinoma [III]

Tumor microenvironmental cellular components like bone marrow cells stromal cells macrophages changes due to sunitinib resistance may affect their efficacy in advanced stage renal cell carcinomas. Immune checkpoint inhibitors (ICIs) have been approved as 2nd line therapy over acquired resistance. Each ICI uniquely affected different cellular components. Better understanding of transcriptomic, metabolomic or proteomic changes due to ICI treatment is necessary to development proper immunotherapy. Overall design: Stromal cells were treated with three ICIs (At: Atezolizumab, Av: Avelumab and D: Durvalumab) for 24hr and RNA was extracted after each treatment. Differential gene expression analysis of each of the treated samples was performed using RNA-seq.

诸如骨髓细胞、基质细胞、巨噬细胞等肿瘤微环境细胞组分，在发生舒尼替尼耐药后产生的改变，可能会影响晚期肾细胞癌的治疗效果。免疫检查点抑制剂（Immune Checkpoint Inhibitors，ICIs）已被批准作为晚期肾细胞癌获得性耐药后的二线治疗方案。不同免疫检查点抑制剂对各类细胞组分的调控效果存在特异性差异。深入解析免疫检查点抑制剂治疗后引发的转录组学、代谢组学或蛋白质组学改变，对于开发适宜的免疫治疗策略至关重要。实验整体设计：将基质细胞分别用三种免疫检查点抑制剂（At：阿替利珠单抗（Atezolizumab）、Av：阿维鲁单抗（Avelumab）、D：度伐利尤单抗（Durvalumab））处理24小时，各处理组完成处理后提取RNA；随后通过RNA测序（RNA-seq）对每一例处理样本进行差异基因表达分析。